Coulter Partners places seasoned medical device R&D leader at Sensome
London, March 3, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Sensome and is pleased to announce the placement of Dr. Brian Burg, as Chief Innovation Officer.
Sensome pioneers microsensing technology for instant intraoperative tissue analysis. Its revolutionary sensor technology transforms invasive medical devices into connected healthcare devices, combining the world’s smallest impedance-based microsensor with machine learning to identify and characterize biological tissues in real-time. The Clotild® clot-sensing guidewire to guide treatment decisions in acute ischemic stroke is the first application of this technology, with further potential applications in interventional radiology and oncology.
Dr. Burg is a highly accomplished engineer and R&D leader driving innovation in medical devices at Sensome. His career blends startup experience, project management expertise (PMP certified), and deep technical knowledge (DrSc). He has a proven track record of guiding complex medical device developments. Prior to Sensome, Brian was Director of R&D at Pixium Vision, leading the development of vision restoration technology. He also held R&D leadership positions at Affluent Medical and CorWave, specializing in Class III medical devices, including implantable and cardiovascular solutions. He has a strong understanding of clinical studies and regulatory processes.
Dr. Burg holds a Doctor of Science in Mechanical Engineering from ETH Zurich (ETH Medal recipient) and completed his postdoctoral studies at MIT. His research background includes heat transfer, energy efficiency, and nanomaterials.
Franz Bozsak, CEO of Sensome said: “We are thrilled to welcome Brian to our team as our Chief Innovation Officer. His extensive experience in medical device R&D, in particular in the development of highly innovative and complex medical devices, makes him an ideal fit for Sensome. Brian’s leadership and deep technical expertise will be invaluable as we expand the applications of our groundbreaking microsensing technology platform to transform the future of minimally invasive procedures with instant intraoperative tissue analysis.”
Commenting on the search work with Coulter Partners, Dr. Bozsak added: “Coulter Partners‘ deep knowledge of the MedTech market, particularly for Class III devices, combined with a unique search strategy, proved invaluable in securing a leader of Brian’s caliber. Their perfect understanding of the needs of a company such as ours was essential to the success of this search.”
[ENDS]
Notes to editors:
About Sensome
Sensome, a clinical-stage health tech start-up, has developed a patented, breakthrough microsensor technology that combines the world’s smallest impedance-based sensor with machine-learning to identify and characterize biological tissues in real-time. The technology is currently being studied in three different clinical indications: clot characterization (ischemic stroke), total occlusion characterization (peripheral vascular disease) and in-situ tool-in-lesion confirmation (lung cancer).
Sensome intends to partner with leading medtech companies to design, manufacture and distribute smart medical devices integrating its proprietary microsensing technology. The company is partnered with leading guidewire manufacturer ASAHI INTECC for manufacturing of the Clotild Smart Guidewire System.
For more information, please visit www.sensome.com
About Coulter Partners
We are executive search and leadership development specialists working to build a better future. As advisors and consultants to companies at the cutting edge of Health, Science, and Technology, we are united by our mission to build teams that change the world. Operating uniquely as one global team, we have honed our expertise, platform, and data for over two decades, working across three continents, and in 40 countries. Applying what we learn through our work with boards, leadership teams, and investors in the world’s most innovative companies, we bring together and develop the right people at the right time to propel them to achieve their worthwhile goals.
